Factors Influencing the Response of Patients with Infantile Epileptic Spasms Syndrome to ACTH as Repeated First-Line Therapy
Authors:
Open Access
- 10 March 2025
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (3) , 759-774
Abstract
Introduction The treatment of infantile epileptic spasms syndrome (IESS) aims to achieve spasm control. Current first-line interventions include hormone therapy (adrenocorticotropic hormone [ACTH] and corticosteroids) and vigabatrin. Despite treatment, the response rate remains at around 40%, with some infants experiencing relapse after achieving initial spasm control. In certain cases, a second course of first-line therapy may be warranted. The objective of this study was to perform a secondary analysis of data from our previously published studies to elucidate factors influencing the efficacy of ACTH following its re-administration after the lack of response to the initial first-line treatment or relapse. Methods We conducted a retrospective analysis of clinical data from children with IESS who had experienced treatment failure or relapse following initial first-line therapy and who subsequently received ACTH at our institution as a second first-line treatment. We examined such variables as etiological classification, interval between treatments, age at first epileptic seizure, radiological findings, and changes in pharmacological treatment modalities, with the overall aim to assess the impact of these variables on the short-term response (disappearance of spasms for > 4 weeks and without hypsarrhythmia pattern) to the second administration of the first-line therapy. Results Among the 128 patients with IESS identified and included in the analysis, 50 (39.1%) achieved a short-term response. Comparative analysis indicated that responders had a shorter duration between the initial first-line therapy and the initiation of the second first-line treatment (median 1.00 [interquartile range {IQR} 0.00, 2.00] vs. 1.75 [IQR 0.50, 3.88] months), were younger at the time of the second first-line treatment (median 11 [IQR 8, 17] vs. 16 [IQR 10, 24] months, p = 0.008), and were less likely to present with additional seizure types during spasm episodes (12.0% vs. 28.2%, p = 0.030). A multifactorial regression model indicated that older age at first seizure and a short-term response to initial first-line treatment were associated with a higher likelihood of obtaining an initial response in the subsequent ACTH treatment (odds ratio [OR] 2.69, 95% confidence interval [CI] 1.39, 7.23, p = 0.014 and OR 5.41, 95% CI 1.48, 23.90, p = 0.016, respectively). Conversely, an older age at the time of the initial first-line treatment, an older age at the onset of epileptic spasms, and patients with congenital structural abnormalities without genetic abnormalities were less likely to achieve an initial response in subsequent ACTH treatment (OR 0.85, 95% CI 0.78, 0.92, p < 0.001; OR 0.43, 95% CI 0.16, 0.82, p = 0.032; and OR 0.18, 95% CI 0.04, 0.69, p = 0.016, respectively).. Conclusion A second ACTH therapy regimen (second first-line treatment) may help some children with IESS who did not respond to the initial treatment or who subsequently relapsed, with one-third of patients responding in the short-term. Congenital anomalies without genetic abnormalities and older spasm onset age lessen the odds of response, while younger age at ACTH re-treatment could improve these. ACTH may be reconsidered after initial treatment response followed by relapse.Keywords
All Related Versions
Funding Information
- General project of Beijing Natural Science Foundation (7222187)
- Epilepsy Research Foundation of Chinese Association Against Epilepsy (CU-B-2021-11)
- Special Scientific Research Project of Military Family Planning (22JSZ20)
- General project of National Key Research and Development Program of China (2023YFC2706405)
This publication has 37 references indexed in Scilit:
- Epilepsy surgery for children with epileptic spasms: A systematic review and meta‐analysis with focus on predictors and outcomesEpilepsia Open, 2024
- Exhaustive clinical examination of etiology and initial response to first‐line treatment in 577 children with infantile epileptic spasm syndrome children: A 5‐year retrospective observational studyAnnals of Clinical and Translational Neurology, 2024
- Epileptic spasms relapse is associated with response latency but not conventional attributes of post‐treatment EEGEpilepsia Open, 2024
- The landscape of infantile epileptic spasms syndrome in South Asia: peculiarities, challenges, and way forwardThe Lancet Regional Health - Southeast Asia, 2023
- Comparing late‐onset epileptic spasm outcomes after corpus callosotomy and subsequent disconnection surgery between post‐encephalitis/encephalopathy and non‐encephalitis/encephalopathyEpilepsia Open, 2023
- Prednisolone or tetracosactide depot for infantile epileptic spasms syndrome? A prospective analysis of data embedded within two randomised controlled trialsEuropean Journal of Paediatric Neurology, 2022
- Integration of multiscale entropy and BASED scale of electroencephalography after adrenocorticotropic hormone therapy predict relapse of infantile spasmsWorld Journal of Pediatrics, 2022
- Incidence and prevalence of major epilepsy-associated brain lesionsEpilepsy & Behavior Reports, 2022
- Infantile spasms: Etiology, lead time and treatment response in a resource limited settingEpilepsy & Behavior Reports, 2020
- Response to treatment in a prospective national infantile spasms cohortAnnals of Neurology, 2015